Ciclopirox is a prescription medication in the United States, regardless of which formulation you use. The 8% nail lacquer (sold under the brand name Penlac), the 1% cream, the gel, the suspension, and the shampoo all require a doctor’s prescription. This catches many people off guard, because plenty of other antifungal products sit on pharmacy shelves without a prescription. The reasons ciclopirox stays behind the prescription counter have to do with its unusual mechanism, the conditions it treats, and regulatory decisions that differ from country to country.
What Ciclopirox Actually Is
Ciclopirox belongs to the hydroxypyridone family of antifungals, which makes it chemically distinct from the azole and allylamine drugs you find in most over-the-counter antifungal creams and sprays. Where most topical antifungals work by disrupting ergosterol, a key component of fungal cell membranes, ciclopirox takes a different approach. It chelates iron and other metal ions that fungi need for their enzymes to function, starving the organism of the tools it uses to break down harmful peroxides and carry out cell division.1PubMed. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent Researchers have also found that it disrupts DNA repair and damages structures involved in cell division inside the fungus.2PubMed Central. Repositioning the Old Fungicide Ciclopirox for New Medical Uses
This unusual mechanism matters practically. Because ciclopirox does not share a target with the azoles (clotrimazole, miconazole, ketoconazole) or the allylamines (terbinafine), it can sometimes work against fungal strains that have developed resistance to those more common drugs. That same distinctiveness, though, means regulatory agencies have treated it differently from the antifungals they eventually moved to OTC status.
Why It Is Not Available Over the Counter in the US
The FDA approved the ciclopirox 8% nail lacquer specifically for mild-to-moderate toenail fungus caused by dermatophytes, and only when the infection has not reached the lunula (the half-moon area at the base of the nail).3PubMed. Ciclopirox nail lacquer and podiatric practice That narrow indication is part of the reason it remains prescription-only. The FDA generally moves drugs to OTC status when the condition is easy for consumers to self-diagnose accurately and the treatment carries low risk of misuse. Nail fungus is famously tricky to self-diagnose: what looks like fungal nails can turn out to be psoriasis, trauma, or other conditions. A misdiagnosis means months of pointless treatment, so the FDA has kept the nail lacquer behind a prescription requirement.
The lower-strength ciclopirox products (1% cream, gel, and shampoo) treat conditions like athlete’s foot, jock itch, ringworm, and seborrheic dermatitis. Even though some of those same conditions can be treated with OTC clotrimazole or terbinafine cream, no manufacturer has pursued an OTC switch for ciclopirox in the US. Switching a drug’s status requires the manufacturer to submit data and applications to the FDA, and the commercial incentive to do so has apparently not been strong enough given how many cheaper OTC alternatives already exist. The result is that every ciclopirox product you can buy in the US still requires a prescription.
The International Picture Looks Different
If you have traveled in Europe or purchased medications internationally, you may have seen ciclopirox products on pharmacy shelves without a prescription. Regulatory classifications vary by country, and several European nations allow certain ciclopirox formulations to be dispensed without a doctor’s order. In parts of Asia and Latin America, availability also varies. This is a common source of confusion online, where someone in Germany describes buying ciclopirox cream over the counter and an American reader assumes they can do the same. In the US, the answer remains no for all formulations.
Available Formulations and What They Treat
Ciclopirox comes in several forms, each aimed at a different type of fungal infection or location on the body:
- 8% nail lacquer: Applied to infected toenails and fingernails for onychomycosis (nail fungus). You paint it on like nail polish, and it dries into a film that delivers the drug through the nail plate.
- 1% cream: Used for skin infections like athlete’s foot, jock itch, and ringworm.
- 0.77% gel: Also for skin fungal infections, with a different base that some patients prefer.
- 1% shampoo: Prescribed for seborrheic dermatitis of the scalp (a condition related to yeast overgrowth that causes flaking and itching).
- 1% suspension: Another option for skin infections, sometimes used on areas where cream does not spread well.
All of these require a prescription in the United States. The nail lacquer is by far the most commonly discussed form, because nail fungus is notoriously stubborn and patients are often searching for anything that might help.
How Well the Nail Lacquer Works
Expectations for ciclopirox nail lacquer should be realistic. The pivotal US trials found mycologic cure rates (meaning the fungus was actually eliminated by lab testing) of about 29 to 36 percent, compared to roughly 9 to 11 percent for placebo.4PubMed. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis Complete cure rates, where both the lab tests and the nail’s appearance returned to normal, were even lower, around 6 to 8 percent.5Journal of Clinical and Aesthetic Dermatology. Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics One review bluntly described the therapeutic outcomes as “disappointing,” and noted that the trials even included regular nail debridement (filing down the nail), which is not something every real-world patient does consistently.6PubMed Central. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents
Non-US studies reported somewhat better numbers, with mycologic cure rates ranging from about 47 to 86 percent, though differences in study populations, infection severity, and protocols make direct comparisons tricky.4PubMed. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis Still, the overall picture is that ciclopirox nail lacquer works better than doing nothing but falls well short of oral antifungal drugs like terbinafine or itraconazole, which reach the nail from the inside through the bloodstream. If you have moderate-to-severe nail fungus, a topical-only approach with ciclopirox is unlikely to clear it completely.
The Nail Penetration Problem
One of the core challenges with treating nail fungus topically is getting the drug through the hard keratin of the nail plate to reach the fungus living underneath. The ciclopirox lacquer addresses this partly through concentration: once the volatile solvents in the lacquer evaporate, the remaining film contains roughly 35% ciclopirox, creating a steep concentration gradient that pushes the drug into the nail.7PubMed. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis Lab data show the drug does penetrate through all nail layers and reaches concentrations above what is needed to kill common nail fungus organisms. Very little ciclopirox gets into the bloodstream, even with long-term use, which is good for safety but also a reminder that the drug is staying local.
Researchers have been working on better delivery systems. Experimental formulations using lipid-based enhancers have achieved dramatically higher ciclopirox concentrations in the deep nail layers compared to the standard commercial lacquer.8PubMed. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers Another approach using an enzyme called papain as a penetration enhancer showed roughly threefold higher permeation than the marketed lacquer.9PubMed. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis These are not yet available to consumers, but they suggest that the drug itself might perform better if it could simply get to where it needs to go more efficiently.
How Ciclopirox Compares to OTC Antifungal Options
If you are dealing with a common skin fungal infection like athlete’s foot or ringworm rather than nail fungus, you have several OTC options available without seeing a doctor. Clotrimazole (Lotrimin), miconazole (Monistat, Micatin), and terbinafine (Lamisil AT) are all sold over the counter in cream or spray form. Pharmacoeconomic analyses have found that terbinafine tended to be the most cost-effective OTC topical for skin fungal infections, clearing infections faster and at a lower overall cost per disease-free day than ciclopirox, clotrimazole, ketoconazole, or miconazole.10PubMed. Pharmacoeconomic analysis of topical treatments for tinea infections One reason is that terbinafine is fungicidal (it kills fungi) and works in one to two weeks for minor skin infections, while the others are generally fungistatic (they stop fungal growth but rely on the body to clear the remaining organisms) and often need four weeks or more.11PubMed. Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections
For skin infections, then, there is little practical reason most people would need prescription ciclopirox when effective OTC antifungals are cheaper and readily available. Ciclopirox becomes more relevant for nail fungus, where OTC creams cannot penetrate the nail plate, and for cases where a doctor wants a drug with a different mechanism than the standard OTC options. Ciclopirox is also used for seborrheic dermatitis, where OTC antifungal shampoos (like ketoconazole 1%) exist but sometimes do not do enough.
Cost and Prescribing Patterns
Even among prescription options for nail fungus, ciclopirox is one of the more affordable choices. A retrospective analysis of Medicare Part D prescribing data from 2016 to 2020 found that the least expensive medications, ciclopirox and terbinafine, accounted for nearly 99 percent of all onychomycosis prescriptions. The newer and more expensive topical agents, efinaconazole and tavaborole, were rarely prescribed. Doctors overwhelmingly chose generic ciclopirox over the brand-name version, prescribing generics 99 percent of the time.12PubMed. Retrospective analysis of onychomycosis prescribing patterns using the medicare part D prescribers database 2016-2020
This tells you something about the practical landscape: while ciclopirox is not the most effective nail fungus treatment available, it is cheap and familiar, which keeps it in wide use. If your doctor prescribes generic ciclopirox nail lacquer, the out-of-pocket cost with insurance is often modest, though without insurance it can still run upward of $50 to $100 for a bottle depending on the pharmacy.
Combination Therapy for Stubborn Nail Fungus
Because ciclopirox nail lacquer alone has limited cure rates, doctors sometimes combine it with an oral antifungal. One study compared oral terbinafine alone to oral terbinafine plus ciclopirox nail lacquer over nine months. The combination group achieved a mycologic cure rate of about 88 percent, compared to roughly 65 percent for terbinafine alone.13PubMed. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis The combination was described as safe and particularly effective in younger patients and in infections that had not been present for very long.
A larger retrospective study looked at patients receiving ciclopirox 8% nail lacquer together with various oral antifungals (terbinafine, itraconazole, or fluconazole). About 60 percent of patients started both treatments at the same time, while the rest staggered them. The response to treatment was positive or likely positive in roughly three-quarters of patients, and the type of oral antifungal or the timing of when treatments were started did not seem to matter much.14PubMed Central. Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records The takeaway for patients is that if your doctor prescribes ciclopirox lacquer alongside an oral pill, the combination is well-supported and significantly more effective than either approach alone.
Safety Profile and Systemic Absorption
One genuine advantage of ciclopirox is its safety. Topical application results in very little of the drug reaching the bloodstream. Studies in animal models found that only about 0.15 percent of the applied dose made it into systemic circulation, and the drug cleared from the skin quickly with a half-life of around two hours.15PubMed. Skin uptake and clearance of ciclopirox following topical application For the nail lacquer specifically, systemic levels remain low even after months of daily use.7PubMed. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis
Side effects are generally limited to the application site: mild redness, burning, or irritation of the surrounding skin for the lacquer, and similar local reactions for the cream and gel. Compared to oral antifungals like terbinafine or itraconazole, which carry risks of liver toxicity and drug interactions, ciclopirox is a much gentler option. For patients who cannot take oral antifungals due to liver disease, drug interactions, or other health concerns, topical ciclopirox may be the only realistic pharmacologic choice for nail fungus.
Antifungal Resistance and Why Ciclopirox Still Matters
Growing resistance to common antifungal drugs is a real concern in dermatology. Terbinafine-resistant strains of the fungus most responsible for nail infections have been increasingly reported in recent years, which makes alternative drugs more important. Topical agents including ciclopirox, efinaconazole, and tavaborole have shown activity against both susceptible and resistant isolates, with low potential for promoting further resistance.16PubMed. Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents Ciclopirox’s unique mechanism, which does not overlap with the targets that resistant fungi have learned to evade, gives it a continued role even as newer agents emerge.
Emerging Alternatives and Newer Topical Agents
Since ciclopirox was for years the only FDA-approved topical for nail fungus in the US, it occupied the market by default. That changed with the approval of efinaconazole 10% solution (Jublia) and tavaborole 5% solution (Kerydin), both of which showed higher complete cure rates in clinical trials than ciclopirox had achieved. These newer topicals are also prescription-only, and they are substantially more expensive, which explains why their prescribing rates remain low despite better efficacy data.
Research into non-drug alternatives continues as well. A recent randomized trial compared ciclopirox 8% nail lacquer to a combination of diode laser and photodynamic therapy. The laser group achieved a clinical cure rate of about 94 percent versus roughly 53 percent for ciclopirox, and healed in an average of about 3.6 months compared to over 9 months for the lacquer. However, the laser group had side effects like blisters and blood under the nail in about 11 percent of cases, and a recurrence rate of about 33 percent. The ciclopirox group had no adverse events and no recurrences.17PubMed Central. Diode Laser and Red-Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial That trade-off between speed of cure and gentleness of treatment is worth discussing with your dermatologist.
Beyond Fungal Infections
Ciclopirox has attracted research attention for uses far outside its original antifungal indication. Its iron-chelating properties turn out to interfere with processes that cancer cells and viruses depend on. Early-stage research has explored ciclopirox as a potential anticancer agent, finding that it can inhibit multiple pathways involved in tumor cell growth and survival. It has also been studied for antiviral activity, with evidence that it can reduce viral replication and alter the immune response to infection. More speculatively, researchers are investigating whether its iron-chelation effects could protect against neurodegenerative diseases like Alzheimer’s and Parkinson’s.18European Journal of Clinical and Experimental Medicine. Exploring the versatility of ciclopirox – from anti-fungal to anticancer agent and beyond None of these uses are approved or anywhere close to clinical practice, but they illustrate why this decades-old antifungal continues to appear in research journals. If any of these indications ever pan out, the regulatory story around ciclopirox could change significantly, but for now it remains what it has been since the 1990s: a prescription topical antifungal with a good safety record and modest efficacy for its main use case in nail fungus.